Cibus, Inc. (CBUS)
NASDAQ: CBUS · Real-Time Price · USD
2.430
+0.285 (13.29%)
At close: May 12, 2025, 4:00 PM
2.390
-0.040 (-1.65%)
After-hours: May 12, 2025, 5:41 PM EDT
Cibus Revenue
Cibus had revenue of $1.03M in the quarter ending March 31, 2025, with 89.72% growth. This brings the company's revenue in the last twelve months to $4.75M, up 104.78% year-over-year. In the year 2024, Cibus had annual revenue of $4.26M with 134.56% growth.
Revenue (ttm)
$4.75M
Revenue Growth
+104.78%
P/S Ratio
13.69
Revenue / Employee
$29,881
Employees
159
Market Cap
83.55M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 4.26M | 2.45M | 134.56% |
Dec 31, 2023 | 1.82M | 1.66M | 1,057.32% |
Dec 31, 2022 | 157.00K | -25.83M | -99.40% |
Dec 31, 2021 | 25.99M | 2.14M | 8.96% |
Dec 31, 2020 | 23.85M | 16.56M | 226.91% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
CBUS News
- 2 days ago - Cibus, Inc. (CBUS) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 4 days ago - Cibus Reports First Quarter Financial Results and Provides Year-to-Date Business Update for 2025 - GlobeNewsWire
- 5 days ago - Ecuador Approves Cibus Herbicide Tolerance Traits as Equivalent to Conventional Breeding - GlobeNewsWire
- 17 days ago - Cibus to Report First Quarter 2025 Financial Results on May 8, 2025 After the Market Close and Host Conference Call - GlobeNewsWire
- 18 days ago - USDA-APHIS Designates Additional Cibus' Disease Resistance Trait Products as Not Regulated - GlobeNewsWire
- 7 weeks ago - Cibus, Inc. (CBUS) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Cibus Reports Fourth Quarter Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Cibus Welcomes the European Union's Progress as Legislation for New Genomic Techniques to Boost Innovation and Sustainability Moves Forward - GlobeNewsWire